Rankings
▼
Calendar
AMRX Q4 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q4 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$537M
+5.3% YoY
Gross Profit
$166M
31.0% margin
Operating Income
$11M
2.1% margin
Net Income
-$6M
-1.2% margin
EPS (Diluted)
$-0.04
QoQ Revenue Growth
+1.6%
Cash Flow
Operating Cash Flow
$63M
Free Cash Flow
$45M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$3.9B
Total Liabilities
$3.6B
Stockholders' Equity
$360M
Cash & Equivalents
$248M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$537M
$510M
+5.3%
Gross Profit
$166M
$167M
-0.4%
Operating Income
$11M
$20M
-44.6%
Net Income
-$6M
-$3M
-110.0%
Revenue Segments
Generics Segment
$346M
77%
Amneal Specialty Pharma Segment
$101M
23%
← FY 2021
All Quarters
Q1 2022 →